Major Shareholder Announcement no. 2, 2012

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has reduced its holding of B shares in Novozymes to 7.71%, previously reported at 7.81% (a decrease of 0.10%).

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has reduced its holding of B shares in Novozymes to 7.71%, previously reported at 7.81% (a decrease of 0.10%).
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 25,072,500 shares of a nominal value of DKK 50,145,000, equivalent to 7.71% of Novozymes A/S’ share capital and 3.10% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 15,985,952 B shares of a nominal value of DKK 31,971,904, equivalent to 4.92% of Novozymes share capital.
                                                                                                                                         
  
Contact persons:
Press and media:
Investor relations:
René Tronborg (Europe)
Tel. (direct): +45 4446 2274
Tel. (mobile): +45 3077 2274
 
Paige Donnelly (USA)
Tel. (direct): +1 919 494 3209
Tel. (mobile): +1 919 218 4501
Martin Riise
Tel. (direct): +45 4446 0738
Tel. (mobile): +45 3077 0738
 
Thomas Bomhoff (USA)
Tel. (direct): +1 919 494 3483
Tel. (mobile):  +1 919 649 2565